Swing Therapeutics Interview
We are thrilled to be joined by Swing Therapeutics for this special presentation of Fibromyalgia Research In Action! Swing Therapeutics was founded in 2019 with the goal of developing digital treatments in disease areas where patients are not well-served, and where digital interventions may be effective. Its focus is on tackling autoimmune conditions and chronic overlapping pain conditions (COPCs) like fibromyalgia where central pain sensitization is a significant factor. The company is investing in research to support the development and validation of its pipeline of prescription-based digital therapies. Swing Therapeutics’ near-term goal is to validate its digital program for the treatment of fibromyalgia and bring it to market as an FDA-cleared, prescription-based digital therapeutic.
Enjoy our interview with two integral members from the Swing team – Steph Catella, PsyD and Jeremy Frank, PhD.
If you are interested in participating in REACT-FM: GO HERE
The mission at Swing is to create evidence-backed digital treatments to help people with chronic conditions live their best lives. Learn more about their company here: SwingTherapeutics.com
For our Fibromyalgia Research In Action program we believe in making research information accessible. We connect you behind the scenes with the wonderful people conducting fibromyalgia research and we rally the fibromyalgia community to support their wonderful work. Thank you for supporting fibromyalgia research!
This Post Has 0 Comments